These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
162 related articles for article (PubMed ID: 20838065)
1. Management of the cutaneous side effects of therapeutic epidermal growth factor receptor inhibition. Reck M; Gutzmer R Onkologie; 2010; 33(8-9):470-9. PubMed ID: 20838065 [TBL] [Abstract][Full Text] [Related]
2. Clinical approaches to minimize rash associated with EGFR inhibitors. Oishi K Oncol Nurs Forum; 2008 Jan; 35(1):103-11. PubMed ID: 18192159 [TBL] [Abstract][Full Text] [Related]
3. HER1/EGFR inhibitor-associated rash: future directions for management and investigation outcomes from the HER1/EGFR inhibitor rash management forum. Pérez-Soler R; Delord JP; Halpern A; Kelly K; Krueger J; Sureda BM; von Pawel J; Temel J; Siena S; Soulières D; Saltz L; Leyden J Oncologist; 2005 May; 10(5):345-56. PubMed ID: 15851793 [TBL] [Abstract][Full Text] [Related]
4. Evidence-based treatment options for the management of skin toxicities associated with epidermal growth factor receptor inhibitors. Tan EH; Chan A Ann Pharmacother; 2009 Oct; 43(10):1658-66. PubMed ID: 19755624 [TBL] [Abstract][Full Text] [Related]
5. Toward evidence-based management of the dermatologic effects of EGFR inhibitors. LoRusso P Oncology (Williston Park); 2009 Feb; 23(2):186-94. PubMed ID: 19323301 [TBL] [Abstract][Full Text] [Related]
7. Cutaneous side-effects of EGFR inhibitors and their management. Ehmann LM; Ruzicka T; Wollenberg A Skin Therapy Lett; 2011 Jan; 16(1):1-3. PubMed ID: 21293833 [TBL] [Abstract][Full Text] [Related]
8. Treatment of epidermal growth factor receptor antagonist-induced skin rash: results of a survey among German oncologists. Hassel JC; Kripp M; Al-Batran S; Hofheinz RD Onkologie; 2010; 33(3):94-8. PubMed ID: 20215799 [TBL] [Abstract][Full Text] [Related]
9. Pimecrolimus cream 1% for the treatment of papulopustular eruption related to epidermal growth factor receptor inhibitors: a case series and a literature review of therapeutic approaches. Nikolaou V; Stratigos A; Antoniou C; Kiagia M; Nikolaou C; Katsambas A; Syrigos K Dermatology; 2010; 220(3):243-8. PubMed ID: 20110632 [TBL] [Abstract][Full Text] [Related]
10. Manage skin toxicities associated with EGFR inhibitors. Becze E ONS Connect; 2008 Jun; 23(6):22-3. PubMed ID: 18572873 [No Abstract] [Full Text] [Related]
11. Impact and management of skin toxicity associated with anti-epidermal growth factor receptor therapy: survey results. Boone SL; Rademaker A; Liu D; Pfeiffer C; Mauro DJ; Lacouture ME Oncology; 2007; 72(3-4):152-9. PubMed ID: 18160805 [TBL] [Abstract][Full Text] [Related]
12. Management of cutaneous side effects of EGFR inhibitors: recommendations from a German expert panel for the primary treating physician. Gutzmer R; Becker JC; Enk A; Garbe C; Hauschild A; Leverkus M; Reimer G; Treudler R; Tsianakas A; Ulrich C; Wollenberg A; Homey B J Dtsch Dermatol Ges; 2011 Mar; 9(3):195-203. PubMed ID: 21059173 [TBL] [Abstract][Full Text] [Related]
13. Cutaneous adverse effects with HER1/EGFR-targeted agents: is there a silver lining? Peréz-Soler R; Saltz L J Clin Oncol; 2005 Aug; 23(22):5235-46. PubMed ID: 16051966 [TBL] [Abstract][Full Text] [Related]
14. What kind of rash is it?: deciphering the dermatologic toxicities of biologic and targeted therapies. Esper P; Gale D; Muehlbauer P Clin J Oncol Nurs; 2007 Oct; 11(5):659-66. PubMed ID: 17962174 [TBL] [Abstract][Full Text] [Related]
15. Clinical research of EGFR inhibitors and related dermatologic toxicities. Perez-Soler R; Van Cutsem E Oncology (Williston Park); 2007 Oct; 21(11 Suppl 5):10-6. PubMed ID: 18154213 [TBL] [Abstract][Full Text] [Related]
16. Epidermal growth factor receptor inhibitor-associated cutaneous toxicities: an evolving paradigm in clinical management. Lynch TJ; Kim ES; Eaby B; Garey J; West DP; Lacouture ME Oncologist; 2007 May; 12(5):610-21. PubMed ID: 17522250 [TBL] [Abstract][Full Text] [Related]
17. Increased risk of high-grade dermatologic toxicities with radiation plus epidermal growth factor receptor inhibitor therapy. Tejwani A; Wu S; Jia Y; Agulnik M; Millender L; Lacouture ME Cancer; 2009 Mar; 115(6):1286-99. PubMed ID: 19170238 [TBL] [Abstract][Full Text] [Related]